Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04713371 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial for Patients With Metastatic Solid Cancer
A Phase 2 study of Metastatic Cancer, sponsored by Rampart Health, L.L.C..
- Active
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04713371 is a Phase 2 study of Metastatic Cancer that is active but no longer recruiting, run by Rampart Health, L.L.C.. The registered enrollment target is 32 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04713371, a Phase 2 study of Metastatic Cancer, is active but no longer recruiting, sponsored by Rampart Health, L.L.C..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to estimate the potential efficacy of the study treatment, as well as the occurrence of adverse events.
Conditions Studied
Interventions
- DRUG Cytoxan
- DRUG Keytruda Injectable Product
- DRUG Yervoy Injectable Product
- PROCEDURE Cryosurgical freezing (cryosurgery)
- DRUG GM-CSF Injectable
Study Locations (1)
Michigan
- Ascension Providence Rochester Hospital - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-05-19 |
| Est. Completion | 2024-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04713371
The ClinicalTrials.gov registry entry for NCT04713371 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Rampart Health, L.L.C., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cytoxan is the first listed.
NCT04713371 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT04713371 about?
NCT04713371 is a clinical study titled "A Phase 2 Trial for Patients With Metastatic Solid Cancer". This study seeks to estimate the potential efficacy of the study treatment, as well as the occurrence of adverse events.
What is the current status of trial NCT04713371?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2021-05-19. Estimated completion is 2024-12.
What conditions does trial NCT04713371 study?
This clinical trial studies the following conditions: Metastatic Cancer.
What interventions are being tested in trial NCT04713371?
The interventions under investigation include: Cytoxan (DRUG), Keytruda Injectable Product (DRUG), Yervoy Injectable Product (DRUG), Cryosurgical freezing (cryosurgery) (PROCEDURE), GM-CSF Injectable (DRUG).
Who is sponsoring clinical trial NCT04713371?
This trial is sponsored by Rampart Health, L.L.C., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04713371 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Biomarkers to Detect Endocrine Therapy Resistance
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.